Table 1 Patient demographic and clinical characteristics.

Total patients

n (%)

214 (100)

107 (50)

107 (50)

1

107 (50)

107 (50)

1

107 (50)

107 (50)

1

Age

(years) Mean; Median; Range

54.5; 57; 18–75

55.4; 58; 20–75

53.5; 56; 18–74

0.17

55.1; 58; 25–75

53.8; 57; 18–74

0.41

55.0; 58; 20–75

53.9; 57; 18–74

0.29

Sex

(M; F) n (%)

123;91 (57.5;42.5)

66;41 (61.7;38.3)

57;50 (53.3;46.7)

0.21

60;47 (48.8;51.6)

63;44 (51.2;48.4)

0.67

65; 42 (52.8; 46.2)

58; 49 (47.2; 53.8)

0.33

Disease

n (%)

AML

106 (49.5)

55 (51.9)

51 (48.1)

48 (45.3)

58 (54.7)

55 (51.9)

51 (48.1)

ALL

25 (11.7)

6 (24)

19 (76)

9 (36)

16 (64)

10 (40)

15 (60)

MM

10 (4.7)

4 (40)

6 (60)

0.054

4 (40)

6 (60)

0.044

1 (10)

9 (90)

0.094

MDS

30 (14.0)

21 (70)

9 (30)

22 (73.3)

8 (26.7)

19 (63.3)

11 (36.7)

Lymphoma

19 (8.9)

10 (52.6)

9 (47.4)

9 (47.4)

10 (52.6)

8 (42.1)

11 (57.9)

MPN

17 (7.9)

8 (47.1)

9 (52.9)

12 (70.6)

5 (29.4)

10 (58.8)

7 (41.2)

Others

7 (3.3)

3 (42.9)

4 (57.1)

3 (42.9)

4 (57.1)

4 (57.1)

3 (42.9)

HLA matching

n (%)

10;10

146 (68.2)

72 (49.3)

74 (50.7)

71 (48.6)

75 (51.4)

69 (47.3)

77 (52.7)

9;10

61 (28.5)

31 (50.8)

30 (49.2)

0.91

31 (50.8)

30 (49.2)

0.49

34 (55.7)

27 (44.3)

0.5

8;10

7 (3.3)

4 (57.1)

3 (42.9)

5 (71.4)

2 (28.6)

4 (57.1)

3 (42.9)

ECOG pre-HSCT

n (%)

0

180 (85.7)

84 (46.7)

96 (53.3)

88 (48.9)

92 (51.1)

86 (47.8)

94 (52.2)

1

25 (11.9)

16 (64)

9 (36)

0.23

13 (52)

12 (48)

0.85

16 (64)

9 (36)

0.28

2

5 (2.4)

3 (60)

2 (40)

3 (60)

2 (40)

2 (40)

3 (60)

CD34 + (× 106)/kg in the graft

Mean, Median, Range

6.15; 6.2; 1.1–9.4

6.1; 6.3; 1.1–9.4

6.1; 6.2; 2–8.9

0.65

6.2; 6.4; 2–9.3

6; 5.8; 1.1–9

0.24

6.1; 6.3; 2–9.4

6.1; 6; 1.1–9

0.63

Conditioning regimen

MAC n (%)

29 (13.6)

13 (44.8)

16 (55.2)

16 (55.2)

13 (44.8)

13 (44.8)

16 (55.2)

Sequential n (%)

29 (13.6)

19 (65.5)

10 (34.5)

0.18

12 (42.9)

16 (57.1)

0.63

18 (62.1)

11 (37.9)

0.34

RIC n (%)

156 (72.9)

75 (48.1)

81 (51.9)

79 (50.6)

77 (49.4)

76 (48.7)

80 (51.3)

GVHD prophylaxis

Alemtuzumab n (%)

65 (30.4)

36 (55.4)

29 (44.6)

38 (58.5)

27 (41.5)

37 (56.9)

28 (43.1)

ATG (%)

146 (68.2)

71 (48.6)

75 (51.4)

0.14

67 (46.2)

78 (53.8)

0.22

70 (47.9)

76 (52.1)

0.10

Other n (%)

3 (1.4)

0 (0)

3 (100)

2 (66.7)

1 (33.3)

0 (0)

3 (100)

HCT-CI

(Mean, Median, Range)

2.8, 3, 0–12

2.9, 3, 0–12

2.7, 3, 0–8

0.73

2.9, 3, 0–12

2.9, 3, 0–8

0.99

3.0, 3, 0–9

2.7, 3, 0–12

0.22

Duration of hospitalization

(days) Mean, Median, Range

43.6; 35; 12–195

44.6; 35; 12–171

42.6; 35; 15–195

0.67

44; 35; 12–195

43.2; 35; 15–171

0.85

47.5; 35; 12–195

39.6; 35; 14–133

0.26

BMI pre-HSCT

Mean, Median, Range

26.2; 25.6; 18–42

25.9; 25.4; 19–39

26.5; 25.7; 18–42

0.46

26.4; 25.8; 19–42

26; 25.6; 18–39

0.68

26.4; 25.7; 19–42

26; 25.6; 18–39

0.61

Granulocyte reconstitution (> 0.5/nl)

reached (days post-HSCT) Mean, Median, Range

18.5; 18; 9–37

18.3; 17; 10–34

18.7; 18; 9–37

0.54

18; 17; 9–34

19; 18.5; 10–37

0.09

18.3; 17; 10–37

18.7; 18; 9–32

0.31

Transfusions during hospitalization

Red blood cell transfusion (n, Mean, Median, Range)

10.8; 8; 0–100

12.2; 10; 0–100

9.3; 8; 0–50

0.06

10.6; 8; 0–50

11; 8; 0–100

0.57

13.1; 10; 0–50

8.3; 6; 0–100

0.000

Platelet transfusion (n, Mean, Median, Range)

11.6; 8; 0–115

13.3; 9; 0–115

9.8; 6; 0–79

0.03

11.1; 8; 0–79

12; 7; 0–115

0.83

14.5; 10.5; 0–79

8.5; 6; 0–115

0.000

FFP (n, Mean, Median, Range)

0.8; 0; 0–34

0.7; 0; 0–10

0.9; 0; 0–34

0.27

0.58; 0; 0–10

1; 0; 0–34

0.43

1.36; 0; 0–34

0.27; 0; 0–8

0.000

Fever during hospitalization

Days

3.2; 2.0; 0–26

3.6; 2; 0–26

2.8; 2; 0–14

0.22

3.5; 2; 0–26

2.9; 2; 0–14

0.35

3.8; 2; 0–26

2.61; 2; 0–15

0.002

Different antibiotics during hospitalization

Mean, Median, Range

1.9; 2.0; 0–6

2; 2; 0–5

1.7; 1; 0–6

0.05

2; 2; 0–6

1.8; 1; 0–6

0.22

2.1; 2; 0–6

1.6; 1; 0–6

0.005

ICU treatment during hospitalization

n (%)

42 (19.7)

22 (52.4)

20 (47.6)

0.7

24 (57.1)

18 (42.9)

0.31

28 (66.7)

14 (33.3)

0.017

In hospital mortality

Alive n (%)

192 (89.7)

96 (50)

96 (50)

1

96 (50)

96 (50)

1

91 (47.4)

101 (52.6)

0.024

Dead (%)

22 (10.3)

11 (50)

11 (50)

11 (50)

11 (50)

16 (72.7)

6 (27.3)

CMV reactivation

n (%)

90 (42.1)

52 (57.8)

38 (42.2)

0.053

52 (57.8)

38 (42.2)

0.053

47 (52.2)

43 (47.8)

0.58

EBV reactivation

n (%)

49 (22.9)

25 (51)

24 (49)

0.87

22 (44.9)

27 (55.1)

0.41

21 (42.9)

28 (57.1)

0.25

Acute graft versus host disease

Acute GVHD grade 1–4 n (%)

96 (45.9)

48 (50)

48 (50)

0.94

53 (55.2)

43 (44.8)

0.14

48 (50)

48 (50)

0.84

Acute GVHD grade 3–4 n (%)

37 (17.7)

16 (43.2)

21 (56.8)

0.34

21 (56.8)

16 (43.2)

0.34

17 (45.9)

20 (54.1)

0.52

C-reactive Protein (CRP) pre-HSCT

Mean, Median, Range (mg/l)

17.5, 5.2, 0–259

21.8; 5.3; 0–259

13.2; 5.2; 0–138

0.58

21.5; 6.5; 0–259

13.5; 4.6; 0–138

0.37

21.6; 6.3; 0–259

13.4; 4.8; 0–138

0.068

Ferritin pre-HSCT

Mean, Median, Range (ng/ml)

1828, 1099, 12–10,663

2084; 1229; 31–10,663

1558; 1066; 12–10,002

0.15

1736; 912; 42–10,663

1367; 1259; 12–10,002

0.57

2294; 1477; 140–10,663

1337; 754; 12–10,002

0.004

GVHD n (%)

7 (5.4)

3 (42.9)

4 (57.1)

3 (42.9)

4 (57.1)

6 (85.7)

1 (14.3)

Causes of death

Relapse n (%)

53 (40.8)

25 (47.2)

28 (52.8)

0.76

20 (38.5)

32 (61.5)

0.072

28 (52.8)

25 (47.2)

0.34

Sepsis n (%)

55 (42.3)

31 (56.4)

24 (43.6)

35 (63.6)

20 (36.4)

31 (56.4)

24 (43.6)

Other n (%)

15 (11.5)

8 (53.3)

7 (46.7)

8 (53.3)

7 (46.7)

10 (66.7)

5 (33.3)